Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy

BACKGROUND: Recent phase III clinical trials have established the superiority of the anti-PD-1 antibodies pembrolizumab and nivolumab over the anti-CTLA-4 antibody ipilimumab in the first-line treatment of patients with advanced melanoma. Ipilimumab will be considered for second-line treatment after...

Descripción completa

Detalles Bibliográficos
Autores principales: Bowyer, S, Prithviraj, P, Lorigan, P, Larkin, J, McArthur, G, Atkinson, V, Millward, M, Khou, M, Diem, S, Ramanujam, S, Kong, B, Liniker, E, Guminski, A, Parente, P, Andrews, M C, Parakh, S, Cebon, J, Long, G V, Carlino, M S, Klein, O
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4865968/
https://www.ncbi.nlm.nih.gov/pubmed/27124339
http://dx.doi.org/10.1038/bjc.2016.107

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4865968/
https://www.ncbi.nlm.nih.gov/pubmed/27124339
http://dx.doi.org/10.1038/bjc.2016.107

Ejemplares similares